ClinicalTrials.gg
RecruitingNCT07019714Updated Sep 29, 2026

Daoyin Technique for Improving Exercise Endurance in IPF

An interventional study of Daoyin Technique and Routine Comprehensive Training in Idiopathic Pulmonary Fibrosis, sponsored by Affiliated Hospital of Liaoning University of Traditional Chinese Medicine. Recruiting at 3 sites in China. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Affiliated Hospital of Liaoning University of Traditional Chinese Medicine · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Sep 29, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Planned enrollment
21st of 60
236 · median 83
Started
2026
with 12 others
No phase
3 of 67
2 open now
Primary completion
2028-05
later than 16 of 28 live
Registered
49th of 67
by date

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 21st largest by planned enrollment of the 60 interventional ones that give a count, is one of 13 that started in 2026, is one of 3 with no phase, reaches primary completion later than 16 of the 28 other live ones, and was the 49th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

This study is based on the previously constructed digital rehabilitation management platform, scientifically evaluating the clinical efficacy of guided technology in improving IPF exercise endurance, and forming high-quality clinical evidence.

Read the detailed description

This study is based on a digital and intelligent rehabilitation management platform. It collects patients' movement data through intelligent motion capture equipment and heart rate, blood oxygen, and other data using fitness trackers, to complete rehabilitation tracking management, real-time assessment, and effect evaluation. Adopting a multi-center,non inferiority, randomized controlled clinical trial design, 236 IPF patients were selected as the research subjects. Based on the guideline-directed treatment, the experimental group received guided techniques, while the control group received conventional comprehensive training. The intervention lasted for 3 months, followed by a 3-month follow-up. The primary outcome measures were 6MWD and 30- second sit-to-stand test, while secondary outcome measures included acute exacerbation, FVC, DLCO, VO2 peak, mMRC score, ATAQ-IPF score, etc. The study elucidated the mechanism of action, scientifically evaluated the impact of guided techniques on IPF endurance, and established a guided technique protocol for IPF.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Idiopathic Pulmonary Fibrosis
  • Daoyin Technique
  • randomized controlled trial
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who meet the diagnostic criteria for IPF;
  2. Those who can tolerate guided - technique training;
  3. Aged between 40 and 85 years old;
  4. Those who can independently or with the assistance of family members use devices such as smartphones and computers during home - based training;
  5. Those who voluntarily accept treatment and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Patients in the acute exacerbation phase of IPF.
  2. Patients with comorbidities such as , lung cancer, active pulmonary tuberculosis, bronchiectasis, pulmonary embolism, and other pulmonary diseases.
  3. Patients with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, unstable angina pectoris, acute myocardial infarction, cardiac function at grade 3 or above, stroke, cerebral hemorrhage, etc.).
  4. Patients with severe liver diseases (such as bleeding caused by liver cirrhosis, portal hypertension, and esophagogastric varices) and severe kidney diseases (dialysis, kidney transplantation, etc.).
  5. Patients with severe osteoarthropathy or osteoporosis, and those with unstable fractures.
  6. Patients with progressive neuromuscular diseases.
  7. Patients with unclear consciousness, dementia, and various mental illnesses.
  8. Pregnant or lactating women, and patients with a recent pregnancy plan.
  9. Patients who have been participating in other clinical trials within 1 month before enrollment.
  10. Patients who need long - term use of ventilators and those with unstable vital signs while bedridden.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
236 participants (estimated)

Study arms

  • Experimental
    Daoyin Technique in addition to the guideline - directed treatment.

    The experimental group was given Daoyin Technique in addition to the treatment guided by the guideline "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline "

    Behavioral: Daoyin Technique

  • Active comparator
    Routine Comprehensive Training in addition to the guideline - directed treatment.

    The experimental group was given routine Comprehensive Training in addition to the treatment guided by the guideline "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline "

    Behavioral: Routine Comprehensive Training

Interventions

  • BehavioralDaoyin Technique

    On the basis of treatment guided by "Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline ", the experimental group was given Daoyin Technique for treatment. For patients who are able to complete the respiratory guidance technique. For patients who are unable to complete the respiratory guidance technique but have stable vital signs (referring to the "Expert Consensus on Respiratory Critical Care Rehabilitation Treatment Techniques in China"), the supine guidance technique is selected. It is carried out 5 days a week, 2 times a day, and each training session lasts for 30 minutes.

  • BehavioralRoutine Comprehensive Training

    On the basis of treatment guided by I"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline",the experimental group was given Routine Comprehensive Training. According to the patient's condition, select aerobic training (such as walking) or upper - limb and lower - limb resistance training (such as lifting, chest - expanding, foot - pedaling movements, etc.) combined with respiratory training (such as pursed - lip breathing, abdominal breathing, etc.). The heart rate should reach the target heart rate range and last for more than 10 minutes. This training is carried out 5 days a week, 2 times a day.

06

What researchers measure

Primary outcomes

  1. 6 Six Minute Walk Distance(6MWD)

    6MWD will be applied to evaluate the exercise capacity. The higher values indicate the better exercise capacity.

    Time frame: Change from baseline 6MWD at week 13 and 26.

  2. the 30 - second sit - to - stand test(30s STS)

    30s STS will be used to assess pulmonary function.

    Time frame: Change from baseline FVC at week 13 and 26.

Secondary outcomes

  1. The time of the first acute exacerbation

    The time of the patients' first acute exacerbation will be recorded.

    Time frame: Up to week 26.

  2. Frequency of acute exacerbation

    Frequency of acute exacerbation will be recorded.

    Time frame: Up to week 26.

  3. Frequency of acute exacerbations resulting in hospitalization

    Frequency of acute exacerbation resulting in hospitalization will be recorded.

    Time frame: Up to week 26.

  4. Frequency of acute exacerbations resulting in ICU admission

    Frequency of acute exacerbation resulting in ICU admission will be recorded.

    Time frame: Up to week 26.

  5. Forced vital capacity (FVC)

    FVC will be used to assess pulmonary function.

    Time frame: Change from baseline FVC at week 13 and 26.

  6. Forced expiratory volume in one second(FEV1)

    FEV1 will be used to assess pulmonary function.

    Time frame: Change from baseline FEV1 at week 13 and 26.

  7. Percent of FEV1#FEV1%#

    FEV1% will be used to assess pulmonary function.

    Time frame: Change from baseline FEV1% at week 13 and 26.

  8. Diffusing Capacity of Carbon Monoxide#DLCO#

    DLCO will be used to assess pulmonary function.

    Time frame: Change from baseline DLCO at week 13 and 26.

  9. Cardiopulmonary Exercise Testing(CPET)

    CPET will be used to evaluate the cardiopulmonary function of the human body during exercise. Parameters such as Peak Oxygen Uptake, Anaerobic Threshold, Breathing Reserve, and ventilatory equivalent for carbon dioxide will be collected.

    Time frame: Change from baseline Peak Oxygen Uptake, Anaerobic Threshold, Breathing Reserve, and ventilatory equivalent for carbon dioxide at week 13 and 26.

  10. Blood oxygen saturation(SpO2)

    SpO2 of the subjects is measured by a finger clip pulse oximeter.

    Time frame: Change from baseline SpO2 at week 13 and 26.

  11. Dyspnea

    Dyspnea will be assessed by 22.modified Medical Research Council(mMRC) scores. A score of 0-4 will be given according to the degree of immediate dyspnea. A higher score indicates a worse condition.

    Time frame: Change from baseline mMRC scores at week 13 and 26.

  12. A Tool to Assess Quality of life (ATAQ-IPF)

    ATAQ - IPF is currently a specialized scale for evaluating the quality of life of patients, consisting of 13 dimensions and 74 items, with each item being scored from 1 to 5 points. A higher score indicates a worse condition.

    Time frame: Change from baseline ATAQ-IPF scores at week 13 and 26.

  13. St. George's respiratory questionnaire (SGRQ)

    SGRQ is a scale used to evaluate the quality of life of patients, which includes three dimensions: symptoms, mobility, and the impact of disease on daily life, with a total of 50 items. A higher score indicates a worse condition.

    Time frame: Change from baseline SGRQ scores at week 13 and 26.

  14. Clinical symptoms and Signs

    Clinical symptoms and Signs will be evaluated through a scale. The scale includes coughing, expectoration, chest tightness, shortness of breath, wheezin. The Clinical Symptom Rating Scale includes 6 items: cough, expectoration, chest tightness, shortness of breath, wheezing, and cyanosis. Each item has a score of 0-3, totaling 18 points. The higher the score, the worse he patient's condition.

    Time frame: Change from baseline clinical symptoms and signs up at week 13 and 26.

  15. Imaging findings

    Imaging findings will bedetected by High - Resolution Computed Tomography (HRCT) of the chest.

    Time frame: Up to week 13, 26.

07

Study locations

3 of 3 sites recruiting
  • Xiyuan Hospital of China Academy of Chinese Medical Sciences
    Beijing, Beijing Municipality 100091, China
    Recruiting
  • The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
    Zhengzhou, Henan 450000, China
    Recruiting
  • The Affiliated Hospital of Liaoning University of Traditional Chinese Medicinenese Medicine
    Shenyang, Liaoning, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2028, 25 months after the start.

Of 49 non-industry interventional studies with no phase under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 25 months is close to that.

Counting every sponsor, half of 52 studies reached it within 26 months; a quarter within 12 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Jun 2025 → Apr 2026, primary completion Jun 2028 → May 2028 and completion Dec 2028 → Nov 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 13, 2025
StartActual
Apr 22, 2026was Jun 2025
Primary completionEst.
May 30, 2028was Jun 2028
CompletionEst.
Nov 30, 2028was Dec 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
2 sites added. The Affiliated Hospital of Liaoning University of Traditional Chinese Medicinenese Medicine is now Recruiting
Show 2 added (2 China)
  • Xiyuan Hospital of China Academy of Chinese Medical Sciences · Beijing, China
  • The First Affiliated Hospital of Henan University of Traditional Chinese Medicine · Zhengzhou, China
Sep 29, 2026
Start date
Jun 30, 2025→Apr 22, 2026 (actual)
Sep 29, 2026
Primary completion
Jun 30, 2028→May 30, 2028
Sep 29, 2026
Study completion
Dec 30, 2028→Nov 30, 2028
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Not yet recruiting→Recruiting
    2 sites added. The Affiliated Hospital of Liaoning University of Traditional Chinese Medicinenese Medicine is now Recruiting
    Show 2 added (2 China)
    • Xiyuan Hospital of China Academy of Chinese Medical Sciences · Beijing, China
    • The First Affiliated Hospital of Henan University of Traditional Chinese Medicine · Zhengzhou, China
    Start date Jun 30, 2025→Apr 22, 2026 (now actual)
    Primary completion Jun 30, 2028→May 30, 2028
    Study completion Dec 30, 2028→Nov 30, 2028
    + 3 other changes: index terms, verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07019714
Lead sponsor
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Collaborators
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Xiyuan Hospital of China Academy of Chinese Medical Sciences
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Apr 22, 2026
Primary completion
May 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Li-Jian Pang, Ph.D
Contact
1605893852@qq.com
+8615042457760
Xue-qing Yu, Ph.D
Contact
yxqshi@163.com
13525518843

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion